Halozyme sees minimal Medicare rule impact on royalties through 2035
Halozyme expects zero to minimal royalty effects through 2035 from the CMS rule, and says new ENHANZE partnerships should not be affected.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Halozyme Therapeutics (HALO) says its review of CMS's final Medicare drug price negotiation rule suggests its royalty income should be barely touched, at least through 2035. The rule was issued on November 5, 2026.
The company also does not expect the rule to hinder its ability to sign new ENHANZE partnership deals. These are the company's own projections, not reported revenue, which will only show up in future financial disclosures.
The view rests on the current statutory framework and could change if CMS issues further guidance or amends the rules. The details come from TradingView, which cites a Halozyme press release distributed by PR Newswire.
why it matters
The item concerns one company and its royalty stream rather than the broader pharma sector, so its reach for the wider market is limited. Future CMS guidance is the main variable that could alter the company's assessment.
tags
instruments
on polymarket
sources
- Halozyme Therapeutics, Inc. (HALO) Projects Zero To Minimal Royalty Impact Through 2035 — TradingView, 6 November 2026 at 15:04 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗